Abstract
There have been many drugs and biological agents associated with the development of autoimmune side effects and lupus-like syndromes. Because of therapeutic alternatives and the risk of these and other side effects, many of these drugs are rarely used. The development of new pharmacologic and biological agents certainly will result in additional descriptions of the development of autoimmune side effects, such as DIL. Further study of the mechanism of the development of DIL may result in an improved understanding of the pathophysiology of idiopathic SLE and the potential improvement of treatment for patients with SLE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
